Pfizer signs licensing deal with Starna for experimental CAR-T programs

Pfizer has signed an exclusive licensing deal with China-based Starna Therapeutics for three experimental, preclinical in vivo CAR-T programs targeting autoimmune diseases. Pfizer will develop, manufacture and commercialize the programs outside Greater China, and can use Starna’s technology in inflammation, immunology and oncology; the agreement also includes options for additional research and possible expansion into Greater China. Starna will receive $330 million upfront, up to $2.3 billion in development and commercial milestone payments, and royalties on sales of any approved products. Pfizer will lead clinical development outside Greater China and make products for initial U.S. trials.



